– USA, NY – Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company and its affiliate Beyond Cancer today announced the appointments of David Dvorak and Dr. Gregory Berk to the Board of Directors of Beyond Cancer.
Following these appointments, the Beyond Cancer Board of Directors will be comprised of six members.
“I am excited to announce the addition of two highly-talented and successful industry veterans to broaden Beyond Cancer’s skill set and complete our Board. I have no doubt that the decades of experience brought by Mr. Dvorak and Dr. Berk as healthcare leaders will enhance our ability to successfully meet our timelines and execute on our strategic objectives as we continue to invest in UNO therapy for the treatment of solid tumors. We remain on track to enter first in human studies in the first half of this calendar year and will continue providing updates on our progress.” said Dr. Selena Chaisson, CEO of Beyond Cancer.
About David Dvorak
David Dvorak is a highly successful, recognized healthcare executive with over 25 years of operating experience building globally leading medical device companies. From 2001 to 2007, he served at Zimmer Biomet Holdings, Inc. in positions with increasing responsibility, culminating in him being named the President and CEO from 2007 to 2017. Under his leadership, Zimmer Biomet grew into a Fortune 500 Company with operations in more than 25 countries and products sold in more than 100 countries. During his tenure, revenues increased from $1.2 billion to $7.7 billion and enterprise value from $6.6 billion to $36.0 billion, while Zimmer Biomet embraced an innovative, patient-centric approach delivering value to healthcare providers and patients. Mr. Dvorak has successfully consummated and integrated 30 strategic acquisitions with an aggregate consideration of $20 billion and over $800 million in operating synergies, notably championing the $13.4 billion acquisition and integration of Biomet in 2014. Before Zimmer Biomet, Mr. Dvorak served as an executive officer with STERIS Corporation and has been on the Board of Directors of St. Jude Medical, Inc., the Advanced Medical Technology Association, and the Orthopaedic Research and Education Foundation.
Mr. Dvorak is currently the CEO and Chairman of the Board at DeepThink Health, Inc., Executive Chairman of the Board of Directors of THINK Surgical, Inc., and Managing Director at Black Lake Expeditions, LLC. He received a BS in Finance from Miami University in Oxford, Ohio in 1985, and earned a J.D., magna cum laude, from Case Western Reserve University School of Law in 1991, where he was elected to the Order of the Coif.
About Dr. Gregory Berk
Dr. Gregory Berk joins Beyond Cancer’s Board of Directors with over three decades of medical experience specifically focusing on the oncology pipeline for biotechnology companies, executing operationally across clinical trials, drug development, and regulatory strategy. Dr. Berk currently serves as the President of Research & Development and CMO of GT Biopharma, a clinical-stage immuno-oncology company, while also leading the company as interim CEO. Before GT Biopharma, Dr. Berk served as the CMO of Celularity, where he led the company’s oncology, infectious and degenerative disease programs. Dr. Berk also held executive roles at Verastem, Sideris Pharmaceuticals, BIND Therapeutics, Abraxis BioScience, and Intellikine, the latter of which was acquired in 2011 by Takeda Pharmaceuticals and Millennium for as much as $310 million ($190 million cash upfront and $120 million in milestone payments) for its oncology pipeline. Dr. Berk also served on the integration leadership team during the Celgene, $3.7 Billion acquisition of Abraxis in 2010.
Dr. Berk received his BS in Biochemistry from Tulane University, graduated summa cum laude, and earned his medical degree from Case Western Reserve University in 1984. He completed his internship and residency in internal medicine, and fellowship in hematology-oncology at the Weill Medical College of Cornell University and New York-Presbyterian Hospital, where he also served as a faculty member from 1989-2004. During this time, Dr. Berk served as an investigator on several industry-sponsored and cooperative group oncology clinical trials, including the pivotal trials for Gleevec and Avastin.
About Beyond Air, Inc.
Beyond Air, Inc. is a clinical-stage medical device and biopharmaceutical company developing a revolutionary NO Generator and Delivery System, LungFit, that uses NO generated from ambient air to deliver precise amounts of NO to the lungs for the potential treatment of a variety of pulmonary diseases. The LungFit can generate up to 400 ppm of NO, for delivery either continuously or for a fixed amount of time and can either titrate the dose on-demand or maintain a constant dose. The Company is currently applying its therapeutic expertise to develop treatments for pulmonary hypertension in various settings, in addition to treatments for respiratory tract infections that are not effectively addressed with current standards of care. Beyond Air is currently advancing its revolutionary LungFit for clinical trials for the treatment of severe lung infections such as acute viral pneumonia (including COVID-19) and nontuberculous mycobacteria. Additionally, Beyond Air, through its affiliate, Beyond Cancer, is using ultra-high concentrations of NO with a proprietary delivery system to target certain solid tumors in the pre-clinical setting.
For more information: https://www.beyondair.net/
About Beyond Cancer
Cancer is the second leading cause of death globally, with tumor metastases responsible for approximately 90% of all cancer-related deaths. Current cancer treatment modalities generally include chemotherapy, immunotherapy, radiation, and/or surgery. Nitric oxide at ultra-high concentrations has been reported to show anticancer properties and to serve as a potential chemosensitizer and radiotherapy enhancer. Based on its current findings, Beyond Cancer is developing treatment protocols using ultra-high nitric oxide concentrations to ablate primary tumors and treat metastatic disease.
For more information: https://beyondcancer.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
